TY - JOUR
T1 - Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR)
T2 - An International Multicenter Analysis
AU - the E-AHPBA DP-CAR study group
AU - Klompmaker, Sjors
AU - Peters, Niek A.
AU - van Hilst, Jony
AU - Bassi, Claudio
AU - Boggi, Ugo
AU - Busch, Olivier R.
AU - Niesen, Willem
AU - Van Gulik, Thomas M.
AU - Javed, Ammar A.
AU - Kleeff, Jorg
AU - Kawai, Manabu
AU - Lesurtel, Mickael
AU - Lombardo, Carlo
AU - Moser, A. James
AU - Okada, Ken ichi
AU - Popescu, Irinel
AU - Prasad, Raj
AU - Salvia, Roberto
AU - Sauvanet, Alain
AU - Sturesson, Christian
AU - Weiss, Matthew J.
AU - Zeh, Herbert J.
AU - Zureikat, Amer H.
AU - Yamaue, Hiroki
AU - Wolfgang, Christopher L.
AU - Hogg, Melissa E.
AU - Besselink, Marc G.
AU - Gerritsen, Sarah L.
AU - Adham, Mustapha
AU - Albiol Quer, M. Teresa
AU - Berrevoet, Frederik
AU - Cesaretti, Manuela
AU - Dalla Valle, Raffaele
AU - Darnis, Benjamin
AU - Diener, Markus K.
AU - Del Chiaro, Marco
AU - Hackert, Thilo H.
AU - Grützmann, Robert
AU - Dumitrascu, Traian
AU - Friess, Helmut
AU - Hirono, Seiko
AU - Ivanecz, Arpad
AU - Karayiannakis, Anastasios
AU - Fusai, Giuseppe K.
AU - Labori, Knut J.
AU - López-Ben, Santiago
AU - Mabrut, Jean Yves
AU - Miyazawa, Motoki
AU - Niesen, Willem
AU - Pardo, Fernando
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/3/15
Y1 - 2019/3/15
N2 - Background: Distal pancreatectomy with celiac axis resection (DP-CAR) is a treatment option for selected patients with pancreatic cancer involving the celiac axis. A recent multicenter European study reported a 90-day mortality rate of 16%, highlighting the importance of patient selection. The authors constructed a risk score to predict 90-day mortality and assessed oncologic outcomes. Methods: This multicenter retrospective cohort study investigated patients undergoing DP-CAR at 20 European centers from 12 countries (model design 2000–2016) and three very-high-volume international centers in the United States and Japan (model validation 2004–2017). The area under receiver operator curve (AUC) and calibration plots were used for validation of the 90-day mortality risk model. Secondary outcomes included resection margin status, adjuvant therapy, and survival. Results: For 191 DP-CAR patients, the 90-day mortality rate was 5.5% (95 confidence interval [CI], 2.2–11%) at 5 high-volume (≥ 1 DP-CAR/year) and 18% (95 CI, 9–30%) at 18 low-volume DP-CAR centers (P = 0.015). A risk score with age, sex, body mass index (BMI), American Society of Anesthesiologists (ASA) score, multivisceral resection, open versus minimally invasive surgery, and low- versus high-volume center performed well in both the design and validation cohorts (AUC, 0.79 vs 0.74; P = 0.642). For 174 patients with pancreatic ductal adenocarcinoma, the R0 resection rate was 60%, neoadjuvant and adjuvant therapies were applied for respectively 69% and 67% of the patients, and the median overall survival period was 19 months (95 CI, 15–25 months). Conclusions: When performed for selected patients at high-volume centers, DP-CAR is associated with acceptable 90-day mortality and overall survival. The authors propose a 90-day mortality risk score to improve patient selection and outcomes, with DP-CAR volume as the dominant predictor.
AB - Background: Distal pancreatectomy with celiac axis resection (DP-CAR) is a treatment option for selected patients with pancreatic cancer involving the celiac axis. A recent multicenter European study reported a 90-day mortality rate of 16%, highlighting the importance of patient selection. The authors constructed a risk score to predict 90-day mortality and assessed oncologic outcomes. Methods: This multicenter retrospective cohort study investigated patients undergoing DP-CAR at 20 European centers from 12 countries (model design 2000–2016) and three very-high-volume international centers in the United States and Japan (model validation 2004–2017). The area under receiver operator curve (AUC) and calibration plots were used for validation of the 90-day mortality risk model. Secondary outcomes included resection margin status, adjuvant therapy, and survival. Results: For 191 DP-CAR patients, the 90-day mortality rate was 5.5% (95 confidence interval [CI], 2.2–11%) at 5 high-volume (≥ 1 DP-CAR/year) and 18% (95 CI, 9–30%) at 18 low-volume DP-CAR centers (P = 0.015). A risk score with age, sex, body mass index (BMI), American Society of Anesthesiologists (ASA) score, multivisceral resection, open versus minimally invasive surgery, and low- versus high-volume center performed well in both the design and validation cohorts (AUC, 0.79 vs 0.74; P = 0.642). For 174 patients with pancreatic ductal adenocarcinoma, the R0 resection rate was 60%, neoadjuvant and adjuvant therapies were applied for respectively 69% and 67% of the patients, and the median overall survival period was 19 months (95 CI, 15–25 months). Conclusions: When performed for selected patients at high-volume centers, DP-CAR is associated with acceptable 90-day mortality and overall survival. The authors propose a 90-day mortality risk score to improve patient selection and outcomes, with DP-CAR volume as the dominant predictor.
UR - http://www.scopus.com/inward/record.url?scp=85058447086&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-07101-0
DO - 10.1245/s10434-018-07101-0
M3 - Article
C2 - 30610560
AN - SCOPUS:85058447086
SN - 1068-9265
VL - 26
SP - 772
EP - 781
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 3
ER -